Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06928662 | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse | recruiting | Phase 1 / Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | recruiting | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 |
| clinicaltrials |
| NCT07583888 | VABu Conditioning in Elderly AML HSCT | recruiting | Phase 2 / Phase 3 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07587840 | CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma | recruiting | Phase 2 | 20 | Liping DouOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05828511 | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment(LINKER-MM4) | recruiting | Phase 1 / Phase 2 | 149 | Regeneron PharmaceuticalsINDUSTRY | 3 | May 13, 2026 | clinicaltrials |
| NCT06611839 | Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML(IDH1-AML-2024) | recruiting | Phase 1 / Phase 2 | 23 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06635681 | Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML(DAV-AML-2024) | recruiting | Phase 2 | 380 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06993675 | Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)(ROTATE) | recruiting | Phase 2 | 50 | Noffar BarOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07259070 | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07261163 | Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma | recruiting | Phase 2 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07299149 | Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma(ZGR in TN FL) | recruiting | Phase 2 | 34 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies(CAR-p40-T) | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | recruiting | Phase 2 | 300 | RenJi HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07225985 | Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07554898 | Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma | recruiting | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06481735 | TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06768905 | IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL | recruiting | Phase 1 / Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06928376 | A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients | recruiting | Phase 2 | 160 | Chinese PLA General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06874946 | Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL(Phase I/II) | recruiting | Phase 1 / Phase 2 | 30 | Peking University People's HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07043894 | Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients | recruiting | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05835466 | Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | recruiting | Phase 2 | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04977180 | Cardioprotection in AML(AML 001) | recruiting | Phase 2 | 70 | University of VirginiaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05099471 | Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia(VIWA-1) | recruiting | Phase 2 | 80 | Christian BuskeOTHER | 2 | May 5, 2026 | clinicaltrials |
| NCT05529069 | Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05848765 | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy(REFRACT) | recruiting | Phase 2 | 284 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05956041 | Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | recruiting | Phase 2 | 23 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06508931 | Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms(DALY PED) | recruiting | Phase 2 | 31 | Miltenyi Biomedicine GmbHINDUSTRY | 4 | May 5, 2026 | clinicaltrials |
| NCT07125872 | Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma | recruiting | Phase 2 | 20 | ImmunityBio, Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT07249905 | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma | recruiting | Phase 1 / Phase 2 | 180 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT07564453 | Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia(FLOW) | recruiting | Phase 2 | 101 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05949931 | Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma | recruiting | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07283679 | Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07563179 | Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | recruiting | Phase 2 / Phase 3 | 316 | Taiho Oncology, Inc.INDUSTRY | 10 | Apr 30, 2026 | clinicaltrials |
| NCT05536349 | Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07075328 | A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Otsuka Medical Devices Co., Ltd. JapanINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06807606 | Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation | recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05680558 | Photopheresis in Early-stage Mycosis Fungoides | recruiting | Phase 2 | 74 | Columbia UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06129734 | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | recruiting | Phase 1 / Phase 2 | 20 | Benjamin TomlinsonOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06050694 | Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)(GRAIL) | recruiting | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06679829 | A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant | recruiting | Phase 2 | 215 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04627753 | Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.(Lemon-C) | recruiting | Phase 2 | 30 | Kim, Seok JinOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04989621 | Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) | recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05245656 | A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma | recruiting | Phase 2 | 90 | Kim, Seok JinOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06263491 | Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06377566 | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | recruiting | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06816134 | Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia | recruiting | Phase 2 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07097363 | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 2 | 18 | University of WashingtonOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03523975 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials